Published in Genes Dev on July 01, 2008
Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol (2009) 3.13
Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle (2011) 2.41
Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol (2011) 2.14
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Macrophage phenotypes during tissue repair. J Leukoc Biol (2013) 1.67
p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J Cell Biol (2011) 1.43
Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm (2013) 1.40
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A (2010) 1.28
Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med (2015) 1.28
Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol (2010) 1.27
PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J Cell Biol (2012) 1.18
Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. PLoS One (2010) 1.16
Genetic effects on gene expression across human tissues. Nature (2017) 1.13
Alteration in cellular morphology, density and distribution in rat vocal fold mucosa following injury. Wound Repair Regen (2009) 1.10
Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration. Front Immunol (2011) 1.08
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Immune modulation of stem cells and regeneration. Cell Stem Cell (2014) 1.07
Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed Res Int (2014) 1.00
Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy. Int J Biochem Cell Biol (2008) 0.98
Shared signaling systems in myeloid cell-mediated muscle regeneration. Development (2014) 0.95
Role of integrin-β3 protein in macrophage polarization and regeneration of injured muscle. J Biol Chem (2011) 0.94
Coronary adventitial cells are linked to perivascular cardiac fibrosis via TGFβ1 signaling in the mdx mouse model of Duchenne muscular dystrophy. J Mol Cell Cardiol (2013) 0.94
A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med (2014) 0.92
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med (2013) 0.92
Intrinsic ability of adult stem cell in skeletal muscle: an effective and replenishable resource to the establishment of pluripotent stem cells. Stem Cells Int (2013) 0.92
Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. EMBO Mol Med (2014) 0.92
Macrophage activation and skeletal muscle healing following traumatic injury. J Pathol (2014) 0.91
Fibrogenic Cell Plasticity Blunts Tissue Regeneration and Aggravates Muscular Dystrophy. Stem Cell Reports (2015) 0.91
Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum Mol Genet (2014) 0.91
Potential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosis. Pulm Med (2011) 0.91
A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo. Blood (2015) 0.90
The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med (2015) 0.90
Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy. Skelet Muscle (2014) 0.89
Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor. Hum Mol Genet (2012) 0.89
Macrophages improve survival, proliferation and migration of engrafted myogenic precursor cells into MDX skeletal muscle. PLoS One (2012) 0.89
Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism. Blood (2016) 0.87
Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of Duchenne muscular dystrophy. Int J Mol Med (2012) 0.87
Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis. Am J Physiol Renal Physiol (2014) 0.86
PKC theta ablation improves healing in a mouse model of muscular dystrophy. PLoS One (2012) 0.85
Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev (2016) 0.85
Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J Am Soc Nephrol (2012) 0.84
Heterozygosity for fibrinogen results in efficient resolution of kidney ischemia reperfusion injury. PLoS One (2012) 0.84
Role of stem/progenitor cells in reparative disorders. Fibrogenesis Tissue Repair (2012) 0.83
Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation. J Cell Mol Med (2008) 0.82
Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle. Mol Ther Methods Clin Dev (2014) 0.81
Simultaneous Pathoproteomic Evaluation of the Dystrophin-Glycoprotein Complex and Secondary Changes in the mdx-4cv Mouse Model of Duchenne Muscular Dystrophy. Biology (Basel) (2015) 0.81
Role of fibrinogen in cerebrovascular dysfunction after traumatic brain injury. Brain Inj (2013) 0.80
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther (2016) 0.80
Concurrent Label-Free Mass Spectrometric Analysis of Dystrophin Isoform Dp427 and the Myofibrosis Marker Collagen in Crude Extracts from mdx-4cv Skeletal Muscles. Proteomes (2015) 0.80
Fibrin binds to collagen and provides a bridge for αVβ3 integrin-dependent contraction of collagen gels. Biochem J (2014) 0.79
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids (2014) 0.79
Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J Cell Biol (2016) 0.78
Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β-amyloid fibrinogen interaction. J Thromb Haemost (2016) 0.78
Genome-wide Mechanosensitive MicroRNA (MechanomiR) Screen Uncovers Dysregulation of Their Regulatory Networks in the mdm Mouse Model of Muscular Dystrophy. J Biol Chem (2015) 0.77
Gene expression study of monocytes/macrophages during early foreign body reaction and identification of potential precursors of myofibroblasts. PLoS One (2010) 0.77
Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy. Hum Mol Genet (2016) 0.76
Evaluation of fibrinogen self-assembly: role of its αC region. J Thromb Haemost (2010) 0.76
Shifts in macrophage cytokine production drive muscle fibrosis. Nat Med (2015) 0.76
Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy. Mol Ther (2016) 0.75
Elastase levels and activity are increased in dystrophic muscle and impair myoblast cell survival, proliferation and differentiation. Sci Rep (2016) 0.75
Expression of intercellular adhesion molecule-1 by myofibers in mdx mice. Muscle Nerve (2015) 0.75
Plasminogen-receptor KT : plasminogen activation and beyond. J Thromb Haemost (2016) 0.75
Circulating Biomarkers for Duchenne Muscular Dystrophy. J Neuromuscul Dis (2015) 0.75
Improvement of endurance of DMD animal model using natural polyphenols. Biomed Res Int (2015) 0.75
The significance of macrophage phenotype in cancer and biomaterials. Clin Transl Med (2014) 0.75
Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease. Acta Neuropathol Commun (2015) 0.75
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy. Expert Opin Orphan Drugs (2016) 0.75
Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest (2017) 0.75
Fibrinogen deficiency suppresses the development of early and delayed radiation enteropathy. World J Gastroenterol (2017) 0.75
Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy. Sci Rep (2017) 0.75
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med (1992) 8.46
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature (1991) 5.40
Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell (1995) 3.53
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol (2001) 3.41
Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev (1995) 3.27
Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 2.57
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol (2005) 1.85
NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol (2006) 1.46
Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol (2006) 1.45
Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol (1995) 1.36
Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol (1998) 1.28
Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul Disord (2005) 1.27
Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood (2001) 1.25
uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol (2007) 1.22
Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol (1999) 1.12
Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood (2002) 1.10
Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood (2003) 1.08
Fibrinogen-CD11b/CD18 interaction activates the NF-kappa B pathway and delays apoptosis in human neutrophils. Eur J Immunol (2003) 1.07
Coagulation and fibrinolysis disorder in muscular dystrophy. Muscle Nerve (2001) 0.95
Hypoxia and inflammation. N Engl J Med (2011) 7.71
Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science (2009) 5.07
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol (2006) 3.18
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood (2004) 3.13
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab (2008) 3.00
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 2.57
Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewal. Cell Stem Cell (2009) 2.53
A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A (2002) 2.53
Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol (2002) 2.51
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res (2004) 2.29
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol (2005) 2.23
Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J Cell Biol (2003) 2.19
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Identification of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res (2007) 2.08
Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med (2003) 1.98
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88